Skip to main content Skip to footer content Disable Carousel Autoplay
Webinar
Microbiology

CLSI M27M44S and M38M51S Webinar

What Has Changed and Beyond: Performance Standards for Antifungal Susceptibility Testing of Yeasts and Filamentous Fungi

Join CLSI for a webinar with the latest update on antifungal susceptibility testing of yeasts and filamentous fungi, CLSI M27M44S and CLSI M38M51S. Gain insights from the authors of the documents and a live expert Q&A panel discussion. Featured topics include:

  • Update on what is new in both supplements, including new breakpoints.
  • How intrinsic resistance can be applied in the clinical mycology laboratory.
  • Brief overview of Epidemiological Cutoff Values (ECVs) and upcoming ECVs soon be published.
  • Ongoing Antifungal Susceptibility Subcommittee projects including Candida auris breakpoints and antifungal MIC reading guideline document.


Date: 19 May 2026 | 1-2:00pm EDT

May 19, 2026
1.00

{{FormatPrice(currentPrice)}}

Free

{{FormatPrice(nonMemberPrice)}} List Price
This is your member pricing.
Notify Me About New Editions
Scope

Learning Objectives:

  • Describe changes and new additions to recent performance standards supplements.
  • Discuss the rationale for breakpoints set for rezafungin vs. Candida species and isavuconazole vs. Aspergillus fumigatus.
  • Define intrinsic resistance and how this can be applied in the clinical mycology laboratory.

Intermediate: Refresher course. Some basic knowledge required, for the experienced staff technologist with some years of experience.


CLSI is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E® Program.

Speakers
David Andes, MD, Chief, Division of Infectious Diseases, University of Wisconsin-Madison
Tanis Dingle PhD, FCCM, D(ABMM), Clinical Microbiologist and Assistant Professor, University of Alberta
Philippe Dufresne, PhD, Head of the Mycology Department at Institut national de santé publique du Québec
Nathan Wiederhold, PharmD, Professor and Director, Fungus Testing Laboratory, UT Health, San Antonio
Scope

Learning Objectives:

  • Describe changes and new additions to recent performance standards supplements.
  • Discuss the rationale for breakpoints set for rezafungin vs. Candida species and isavuconazole vs. Aspergillus fumigatus.
  • Define intrinsic resistance and how this can be applied in the clinical mycology laboratory.

Intermediate: Refresher course. Some basic knowledge required, for the experienced staff technologist with some years of experience.


CLSI is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E® Program.

Speakers
David Andes, MD, Chief, Division of Infectious Diseases, University of Wisconsin-Madison
Tanis Dingle PhD, FCCM, D(ABMM), Clinical Microbiologist and Assistant Professor, University of Alberta
Philippe Dufresne, PhD, Head of the Mycology Department at Institut national de santé publique du Québec
Nathan Wiederhold, PharmD, Professor and Director, Fungus Testing Laboratory, UT Health, San Antonio